Adagene at AACR 2026 with New Data Highlighting Muzastotug Potential for Multiple Tumor Types

Adagene (Nasdaq: ADAG) presented interim Phase 1b/2 data at AACR 2026 showing muzastotug in two triplet regimens produced higher response rates and manageable safety profiles in HCC and MSS CRC.

In HCC, the muzastotug triplet showed ORR 66.7% vs 32.5% (control) and mPFS 8.2 vs 5.5 months; in MSS CRC, dose-dependent ORRs were 25% (10 mg/kg) and 40% (15 mg/kg). FDA previously granted Fast Track for muzastotug+pembrolizumab in MSS mCRC without active liver metastases.

https://www.stocktitan.net/news/ADAG/adagene-presents-two-posters-at-aacr-2026-with-new-data-highlighting-qwckojlqad68.html